BiomX Inc. Files Q1 2024 Report

TL;DR

BiomX Inc. filed its Q1 2024 10-Q. All systems go.

AI Summary

BiomX Inc. filed its quarterly report for the period ending March 31, 2024. The company, formerly known as Chardan Healthcare Acquisition Corp., is incorporated in Delaware and operates in the biological products sector. Its business address is located at 22 Einstein St., 4th Floor, Ness Ziona, Israel.

Why It Matters

This filing provides investors with an update on BiomX Inc.'s financial performance and operational status for the first quarter of 2024.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing standard financial and business information.

Key Players & Entities

• BiomX Inc. (company) — Registrant
• Chardan Healthcare Acquisition Corp. (company) — Former company name
• 20240331 (date) — Conformed period of report
• 20240520 (date) — Filed as of date
• 001-38762 (other) — SEC file number
• 22 Einstein St., 4th Floor, Ness Ziona (location) — Business address

FAQ

Key Financial Figures

• $0.0001 — onsisting of one share of common stock, $0.0001 par value, and one warrant exercisable
• $1 — ( 180,297 ) ( 9,544 ) (*) Less than $1. (**) See Note 9A. (***) See Note 1D.
• $50,000 — gregate gross proceeds of approximately $50,000. See note 1D for further information re

Filing Documents

• ea0206522-10q_biomx.htm (10-Q) — 623KB
• ea020652201ex10-2_biomx.htm (EX-10.2) — 75KB
• ea020652201ex31-1_biomx.htm (EX-31.1) — 8KB
• ea020652201ex31-2_biomx.htm (EX-31.2) — 8KB
• ea020652201ex32_biomx.htm (EX-32) — 5KB
• 0001213900-24-045273.txt ( ) — 4721KB
• phge-20240331.xsd (EX-101.SCH) — 65KB
• phge-20240331_cal.xml (EX-101.CAL) — 41KB
• phge-20240331_def.xml (EX-101.DEF) — 270KB
• phge-20240331_lab.xml (EX-101.LAB) — 511KB
• phge-20240331_pre.xml (EX-101.PRE) — 280KB
• ea0206522-10q_biomx_htm.xml (XML) — 450KB

Financial Information

Part I. Financial Information 1

Financial Statements

Item 1. Financial Statements 1 Condensed Consolidated Balance Sheets (unaudited) F-1 Condensed Consolidated Statements of Operations (unaudited) F-3 Condensed Consolidated Statements of Stockholders' Equity (unaudited) F-4 Condensed Consolidated Statements of Cash Flows (unaudited) F-6 Notes to Condensed Consolidated Financial Statements (unaudited) F-7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 2

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 9

Controls and Procedures

Item 4. Controls and Procedures 9

Other Information

Part II. Other Information 10

Exhibits

Item 6. Exhibits. 10

Signatures

Part III. Signatures 11 i CAUTIONARY This Quarterly Report on Form 10-Q, or the Quarterly Report, includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and other securities laws. The statements contained herein that are not purely historical, are forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "will" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. For example, we are making forward-looking statements when we discuss our business strategy and plans, our clinical and pre-clinical development program, including timing, milestones and the design thereof, including acceptance of regulatory agencies of such design, the potential opportunities for and benefits of the BacteriOphage Lead to Treatment, or BOLT, platform, the potential of our product candidates and the sufficiency of financial resources and financial needs and ability to continue as a going concern. However, you should understand that these statements are not guarantees of performance or results, and there are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from those expressed in the forward-looking statements, including, among others: the ability to generate revenues, and raise sufficient financin

View Full Filing

View this 10-Q filing on SEC EDGAR